Adjuvant Capital invests in life sciences technologies addressing critical global public health challenges, particularly in emerging economies. By focusing on underserved markets and leveraging expertise to accelerate impactful innovations, the firm aims to generate both financial and social returns. The firm targets innovations in infectious diseases (HIV/AIDS, tuberculosis, malaria, tropical diseases, pandemics), maternal/child health, nutrition, and reproductive/sexual health, with a preference for technologies that have already proven safety and efficacy in humans.
Preferred startup development maturity for initial funding deployment.
High-burden public health challenges, neglected infectious diseases, maternal and child health, nutrition, reproductive and sexual health, antimicrobial resistance, pandemic threats
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
